The selection of new NRAS mutations is the principal cause of melanoma reactivation in BRAF- or NRAS-mutant cases, explaining why BRAF-mutant or NRAS-mutant melanomas exhibit the largest resistance to B-Raf inhibitors [1]. This evidence concerns the gene NRAS and melanoma.